- Company
- Pfizer launches 'Prevenar 20' for adults aged 18 years+
- by Whang, byung-woo Jun 11, 2025 06:01am
- Pfizer Korea (CEO and President Dong-wook Oh) announced on June 10 that its 'Prevenar 20,' a 20-valent pneumococcal conjugate vaccine for adults, was launched in early June, and it is now available for vaccination for individuals aged 18 years and older. Prevenar 20 will be supplied to the Korean market for adults through a co-promotion a
- Company
- "Atopic dermatitis treatment…personalized trt. is the key"
- by Whang, byung-woo Jun 11, 2025 06:01am
- "Significant changes are being brought to atopic dermatitis treatment. which can be described as a 'major shift.' As it is a complex disease with various factors involved, establishing criteria for personalized treatment regarding which therapeutic agent to use for each patient is necessary." Atopic dermatitis is one of diseases whose treatme
- Policy
- Speculation high over the new Minister of Health and Welfare
- by Lee, Jeong-Hwan Jun 10, 2025 06:05am
- Speculation is rife over who will become the first Minister of Health and Welfare in Lee Jae-myung's administration. Eun-kyeong Jeong, former Commissioner of the Korea Disease Control and Prevention Agency, who served as the chief campaign advisor for Democratic Party candidate Jae-myung Lee, is widely expected to be appointed as the nex
- InterView
- 'Viatris will lead market with innovation and leadership'
- by Whang, byung-woo Jun 10, 2025 06:04am
- “Viatris Korea is pursuing growth through two pillars: a core brand-focused business and new pipelines. Based on the pillars, we expect to secure growth momentum once again on a global scale.” Viatris Korea is working to strengthen its position in the domestic market by introducing a global innovative pipeline and driving continuous growth
- Company
- Polycythemia vera drug 'Besremi' nearing end of reimb review
- by Eo, Yun-Ho Jun 10, 2025 06:04am
- The polycythemia vera (PV) treatment 'Besremi' has entered the final stage of an insurance reimbursement review process. The Ministry of Health and Welfare (MOHW) has recently ordered the National Health Insurance Service (NHIS) to initiate drug price negotiation for PharmaEssentia Korea's Besremi (ropeginterferon alfa-2b). If the company
- Company
- Celltrion’s Stelara biosimilar Qoyvolma gains EU approval
- by Kim, Jin-Gu Jun 10, 2025 06:03am
- Celltrion announced on the 9th that ‘Qoyvolma,’ its biosimilar version of the autoimmune disease treatment Stelara (ustekinumab) has received marketing authorization from the European Commission (EC). Qoyvolma has been approved with the addition of ▲'ulcerative colitis (UC)' to the existing indications of ‘Steqeyma,' another Stelara bi
- Company
- Next-gen oral breast cancer drugs near commercialization
- by Son, Hyung Min Jun 9, 2025 05:53am
- The arrival of next-generation oral selective estrogen receptor degraders (SERDs) is imminent. At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025&160;which was held in Chicago, USA, from the 30th of last month to the 4th, multinational pharmaceutical companies simultaneously disclosed the results of their Phase III clin
- Company
- K-Bio unveils new cancer drug outcomes at the ASCO meeting
- by Son, Hyung Min Jun 9, 2025 05:53am
- The Korean pharmaceutical and biotech industry has unveiled additional clinical outcomes of drug candidates, such as immunotherapy for cancer, targeted anticancer agents, and bispecific antibodies, under development. Major Korean companies, including Daewha Pharmaceutical, LG Chem, Onconic Therapeutics, ImmuneOncia, and Tium Bio, unveiled th
- Company
- 1st patient enrolled in Phase 2 FDA trial of 'Nugel' in KOR
- by Lee, Seok-Jun Jun 9, 2025 05:51am
- Shaperon announced on June 5 that a Phase 2 Part 2 U.S. Food and Drug Administration (FDA) clinical trial for its atopic dermatitis drug 'Nugel' has enrolled the first patient for clinical trials being conducted in South Korea. This trial is a multinational clinical trial evaluating Nugel's safety and efficacy in 177 patients across 12 cli
- Policy
- BMS’s next-gen targeted drug repotrectinib approved in KOR
- by Lee, Hye-Kyung Jun 9, 2025 05:51am
- BMS Pharmaceuticals' ‘Augtyro Cap (repotrectinib),' which is regarded a next-generation targeted therapy for lung cancer, has been approved in Korea. On the 5th, the Ministry of Food and Drug Safety granted marketing authorization for 2 items - Augtyro Cap 40 mg and 160 mg. Specifically, repotrectinib is indicated as: ▲treatment for
